

08-11-2003

PATENT

8-7-03

RI



102520158

SHEET

TO: Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies).

**Submission Type**

- ☒ New
- ☐ Resubmission (Non-Recordation)

Document ID#: ☐ Correction of PTO ErrorReel #:  Frame #: ☐ Corrective DocumentReel #:  Frame #: **Conveyance Type**☐ Assignment ☐ Security Agreement☐ License ☒ Change of Name☐ Merger ☐ Other 

U.S. Government

(For use ONLY by U.S. Government Agencies)

☐ Departmental File ☐ Secret File**Conveying Party(ies)**☐ Mark if additional names of conveying parties attached

Name	Execution Date		
	Month	Day	Year
Pharmaceutical Royalties, L.L.C.	07	25	03
	/	/	
	/	/	
	/	/	
	/	/	

**Receiving Party**☐ Mark if additional names of receiving parties attachedName (line 1)  Royalty Pharma AG in LiquidationName (line 2) Address (line 1)  Vordergrasse 3Address (line 2)  CH-8200Address (line 3)  Schaffhausen  Switzerland 

City

State/Country

Zip Code

☐ If document to be recorded is an assignment and the receiving party is not domiciled in the United States, an appointment of a domestic representative is attached. (Designation must be a separate document from Assignment)

**Domestic Representative Name and Address**

Enter for the first Receiving Party only.

Name Address (line 1) Address (line 2) Address (line 3) Address (line 4) 

08/08/2003 ECOMPER 00000109 09630198

01 FC:0021

240.00 DP

FOR OFFICE USE ONLY

2003 AUG -7 AM 4:29  
OPR/FINANCE

Mail documents to be recorded with required cover sheet(s) information to:

Mail Stop Assignment Recordation Services, Director of the US Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450

PATENT

REEL: 014351 FRAME: 0828

## Correspondent Name and Address

Area Code and Telephone Number (617) 248-7000

Name Patent Administrator

Address (line 1) Testa, Hurwitz &amp; Thibault, LLP

Address (line 2) High Street Tower

Address (line 3) 125 High Street

Address (line 4) Boston, MA 02110

Pages Enter the total number of pages of the attached conveyance document including any attachments.

1

## Application Number(s) or Patent Number(s)

☐ Mark if additional numbers attached

Enter either the Patent Application Number or the Patent Number (DO NOT ENTER BOTH numbers for the same property).

## Patent Application Number(s)

09/630,198

09/724,138

## Patent Number(s)

5,500,362

5,677,180

5,721,108

6,120,767

## Patent Cooperation Treaty (PCT)

Enter PCT application number  
only if a U.S. Application Number  
has not been assigned.

PCT

PCT

PCT

PCT

PCT

PCT

## Number of Properties

Enter the total number of properties involved.

# 6

## Fee Amount

Fee Amount for Properties Listed (37 CFR 3.41):

\$ 240.00

Method of Payment: Enclosed ☒Deposit Account ☐

Deposit Account

(Enter for payment by deposit account or if additional fees can be charged to the account)

Deposit Account Number

# 20-0531

Authorization to charge additional fees:

Yes ☒No ☐

## Statement and Signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Charges to deposit account are authorized, as indicated herein.

Daniel A. Wilson, Reg. No. 45,508

Name of Person Signing



Signature

8/5/03

Date

**NOTICE OF CHANGE OF NAME**

Royalty Pharma AG in Liquidation, a Swiss stock corporation (having an address of Vordergasse 3, CH-8200, Schaffhausen, Switzerland, and formerly known as Royalty Pharma AG) confirms that it is the successor in interest of PHARMACEUTICAL ROYALTIES, L.L.C. (a Delaware limited liability company) by way of the dissolution of PHARMACEUTICAL ROYALTIES, L.L.C. (effective December 17, 2001) and that Royalty Pharma AG in Liquidation is co-owner and co-assignee of all right, title, and interest in:

U.S. Pat. No. 5,500,362, issued March 19, 1996,  
U.S. Pat. No. 5,677,180, issued October 14, 1997,  
U.S. Pat. No. 5,721,108, issued February 24, 1998,  
U.S. Pat. No. 6,120,767, issued September 19, 2000,  
U.S. Appln. Ser. No. 09/630,198, filed August 1, 2000, and  
U.S. Appln. Ser. No. 09/724,138, filed November 28, 2000.

**IN WITNESS WHEREOF**, the party hereto has caused this Notice of Change of Name document to be duly executed and set their hand and affixed their seal the date set forth below.

**Royalty Pharma AG in Liquidation**

By: \_\_\_\_\_

Name: Jean-Francois Hottinger

Title: Liquidator

Witnessed by: Hallam

Name: Marc Hallam

Date: 25 July 2003